Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360.
The exploratory phase 2 clinical trial used an open-label, fixed-dose design to investigate the safety and efficacy of a single dose of 25mg of COMP360 psilocybin with psychological support, in addition to an SSRI, in 19 participants experiencing treatment-resistant depression. The findings were first announced in December 2021.
A new paper published in the American Journal of Psychiatry discusses the potential problems of using the term “psychedelic-assisted psychotherapy” for all psychedelic treatment modalities.
Published in the American Journal of Psychiatry, and co-authored by executives from Compass Pathways, the paper argues that a blanket “psychedelic-assisted psychotherapy” for all treatments isn’t necessarily accurate or optimal for some cases.
A new study published in the journal of Nordic Studies on Alcohol and Drugs Online shows that microdosing can be associated with an increased sense of authenticity.
This survey study followed a group of people microdosing for one month (a relatively small group of 18 participants) — and focused on feeling of “authenticity”, which they propose is highly related to a sense of well-being.
Shareholders have approved the sale of Reuninon Neuroscience. The deal shows that MPM would acquire Reunion in an all-cash transaction valued at approximately US$13.1 million — taking the company private and bringing it under its group of private subsidiaries.
“…all holders of outstanding common shares of Reunion will be entitled to receive US$1.12 in cash for each Share held immediately prior to the effective time of the Arrangement. Based on the Bank of Canada daily exchange rate as of the close of business on May 31, 2023, this would be approximately $1.52 per Share in Canadian dollars, representing a premium of approximately 43.1% over the trailing 30-trading-day volume weighted average price.”